RxDoctor Payments DataLook up a doctor →

Furhan Yunus, MD

Hematology & Oncology · New Orleans, LANPI 1326048356

Payments from drug & device makers

$421,792in general payments, 2019–2025

Across 379 payments — averaging $1112.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$296K
  • Genentech USA, Inc.$44K
  • GSK$28K
  • Pfizer$20K
  • AbbVie$18K
  • Amgen$6K
  • plus $10K from 44 others
$8,602in research payments, 2019–2025

Across 13 payments — averaging $661.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$6K
  • F. Hoffmann-la Roche AG$2K
  • GSK$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421,792 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.

See all hematology & oncology providers in Louisiana

Medicare billing

Part B allowed, 2024
$107,173
Medicare patients
322
Services billed
2,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →